Tavneos ® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/
“ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’s decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.”
“NICE’s decision represents a major advancement for the treatment of GPA/MPA in the UK,” said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge. “Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.”
“We are delighted about this recommendation for patients in England, Wales and Northern Ireland living with GPA/MPA”, said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “It means that an underserved patient population will have access to a first in class treatment aiming to meet major unmet medical needs. We look forward to continue working with the National Health Service to ensure access to this important medicine for patients across the UK as quickly as possible.”
MHRA approval and the NICE recommendation were based on findings from a comprehensive development program, culminating in the results from the pivotal phase-III trial (ADVOCATE) in 331 patients with ANCA-associated vasculitis (GPA/MPA) in 20 countries. This randomized, controlled trial assigned patients to either oral Tavneos® (30mg twice daily) or oral prednisolone on a tapering schedule. All patients received induction treatment with cyclophosphamide or rituximab. The study met its primary endpoints of disease remission at week 26, defined as Birmingham Vasculitis Activity Score (BVAS) of 0 at week 26 and not taking glucocorticoids for treatment of ANCA-associated vasculitis in the previous 4 weeks, and sustained remission at both weeks 26 and 52 defined as a BVAS of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 52. Compared to a prednisolone-based regimen, the Tavneos®-based regimen demonstrated non-inferiority in terms of remission at week 26, and superiority in terms of sustained remission at week 52. Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of patients receiving Tavneos® and in 39% of those receiving prednisolone.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com
About GPA and MPA
GPA and MPA are the two main forms of ANCA-associated vasculitis which is a systemic disease in which inappropriate activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney and lung as major targets, and may be fatal if not treated.
Treatment of GPA/MPA consists of courses of potent immuno-suppressants, in combination with high-dose glucocorticoids (steroids) for prolonged periods of time. However, the unmet medical need remains high as these patients face significant risk of complications, both from their disease and adverse effects from medications, including from long-term use of glucocorticoids. Treatment goals are to achieve sustainable remission to reduce vascular damage and preserve organ function while minimizing the side effects of current treatments.
About Tavneos® (avacopan)
Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By blocking this receptor (C5aR1) for the pro-inflammatory complement system fragment, C5a on inflammatory cells such as neutrophils, Tavneos® reduces the ability of those cells to do damage in response to C5a activation. Moreover, Tavneos® selective inhibition of only the C5aR1 is expected to leave the formation of the beneficial C5b-9 complex intact.
Tavneos® was developed by ChemoCentryx, Inc., who is also developing Tavneos® for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted Tavneos® orphan-drug designation for ANCA-associated vasculitis, C3G and atypical hemolytic uremic syndrome. The European Commission has granted orphan medicinal product designation for Tavneos® for the treatment of two forms of ANCA-associated vasculitis: MPA and GPA (formerly known as Wegener's granulomatosis), as well as for C3G.
VFMCRP has a licensing agreement with ChemoCentryx, Inc., to commercialize Tavneos® outside the US.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Mobile: +41 79 957 96 73
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Trinseo PMMA Depolymerization Plant Reimagines Plastics Value Chain With Sustainability In Mind6.12.2023 22:30:00 CET | Press release
Trinseo (“Trinseo” or “the Company”) (NYSE: TSE), a specialty material solutions provider, is helping advance the potential of sustainable plastics with the inauguration of its next generation, polymethyl methacrylate (PMMA) depolymerization plant in Rho, Italy. Scheduled to be commissioned in Q1 2024, this demonstration facility marks a pivotal step towards reshaping the plastics ecosystem as part of the circular economy. PMMA, renowned for its versatility in various applications, will be transformed through this advanced recycling and purification process where it can go back into the plastics value chain and support the goal of circularity. This depolymerization operation will be designed to enable the efficient recycling of end-of-life PMMA, as well as other difficult to recycle structures, which will ultimately be used to produce acrylic resins, sheets, and compounds containing recycled materials. This press release features multimedia. View the full release here: https://www.busi
Technology Holdings advises ServiceNow Elite Partner Unifii on its strategic sale to Bain Capital backed Inetum6.12.2023 19:55:00 CET | Press release
Technology Holdings, a global investment bank with offices in North America, Europe and the Asia-Pacific is pleased to announce that it has acted as the exclusive financial advisor to London headquartered Elite ServiceNow partner, Unifii on its strategic sale to Bain Capital backed Inetum, which is headquartered in France. Unifii is the largest independent Elite ServiceNow partner in the United Kingdom and Ireland, and is recognized for its unparalleled expertise in supporting clients through their digital transformation journeys. Unifii enables its clients to achieve successful business outcomes through optimized business workflows. Unifii has a recognized customer ecosystem in multiple sectors, including finance, technology, and the public sector. Its team of certified experts and experienced consultants brings undeniable value to its clients’ national and international projects. With the acquisition of Unifii, Inetum becomes a leading European partner for ServiceNow with nearly 500
Edgio’s Group Vice President of EMEA, Emma Whitmore, to Join the Digital TV Group (DTG) Council6.12.2023 17:00:00 CET | Press release
Edgio, Inc. (Nasdaq: EGIO), the platform of choice for speed, security, and simplicity at the edge, today announced that Emma Whitmore, Group Vice President (GVP) of EMEA, is joining the DTG Council, an important industry steering group, to provide Edgio’s unique perspective and insight on the future of TV distribution. For over 25 years, DTG, the UK's unique, self-funding centre for innovation in digital media technology, has been central to driving digital TV innovation in the UK. The 25-strong member council brings together the best thinkers from across broadcasters, technology providers and manufacturers, including BT, BBC, ITV and Sony, to inform the work, policy and direction of the organisation. Powered by a secure global edge network designed for the unique demands of media, Edgio’s solutions allow companies to operate, monetize and securely deliver video content to millions of global viewers. “Given the wealth of knowledge that Emma brings from more than twenty years in the in
Mavenir CEO Welcomes Recognition of Open RAN Vendor Leadership in ABI Research Ranking6.12.2023 16:19:00 CET | Press release
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/ ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire) Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Ma
GWI Appoints New Chief Technology Officer, Nick Dearden6.12.2023 15:00:00 CET | Press release
GWI, the global consumer research platform, today announced that it has appointed Nick Dearden as Chief Technology Officer, based in its UK headquarters in London. Nick has over 25 years of experience in technology, with his grassroots as a developer. At GWI he will lead the engineering, IT, and security teams and will be responsible for the company's technology and data management strategy. His role is key to driving forward the company’s agenda to build technology that gives people clarity over their audience in the moment they need it. Nick’s role will focus on the ongoing innovation, scaling, and automation of processes that underpin access to data representative of nearly 3 billion people across 50+ markets. With simplification and ease of access to GWI data a key strategic driver, Nick will be responsible for identifying appropriate technology, such as AI, to define the technology strategy to achieve this. This will enable the company to automate and unlock powerful new features